Terms: = Breast cancer AND HOXA9, HOX1, 3205, ENSG00000078399, HOX1G, P31269 AND Prognosis
5 results:
1. MicroRNA-638 inhibits the progression of breast cancer through targeting hoxa9 and suppressing Wnt/β-cadherin pathway.
Xu Q; Zhang Q; Dong M; Yu Y
World J Surg Oncol; 2021 Aug; 19(1):247. PubMed ID: 34416888
[TBL] [Abstract] [Full Text] [Related]
2. DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment.
Sarno F; Nebbioso A; Altucci L
Epigenetics; 2020 May; 15(5):439-453. PubMed ID: 31790636
[TBL] [Abstract] [Full Text] [Related]
3. A long-range interactive DNA methylation marker panel for the promoters of hoxa9 and HOXA10 predicts survival in breast cancer patients.
Park SM; Choi EY; Bae M; Choi JK; Kim YJ
Clin Epigenetics; 2017; 9():73. PubMed ID: 28748001
[TBL] [Abstract] [Full Text] [Related]
4. DNA methylation profiling in the Carolina breast cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival.
Conway K; Edmiston SN; May R; Kuan PF; Chu H; Bryant C; Tse CK; Swift-Scanlan T; Geradts J; Troester MA; Millikan RC
Breast Cancer Res; 2014 Oct; 16(5):450. PubMed ID: 25287138
[TBL] [Abstract] [Full Text] [Related]
5. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression.
Mouw JK; Yui Y; Damiano L; Bainer RO; Lakins JN; Acerbi I; Ou G; Wijekoon AC; Levental KR; Gilbert PM; Hwang ES; Chen YY; Weaver VM
Nat Med; 2014 Apr; 20(4):360-7. PubMed ID: 24633304
[TBL] [Abstract] [Full Text] [Related]
